These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 7483252)
21. Vaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferon. Gupta S; Leutenegger CM; Dean GA; Steckbeck JD; Cole KS; Sparger EE J Virol; 2007 Jan; 81(2):465-73. PubMed ID: 17079309 [TBL] [Abstract][Full Text] [Related]
22. Oral immunization with recombinant listeria monocytogenes controls virus load after vaginal challenge with feline immunodeficiency virus. Stevens R; Howard KE; Nordone S; Burkhard M; Dean GA J Virol; 2004 Aug; 78(15):8210-8. PubMed ID: 15254192 [TBL] [Abstract][Full Text] [Related]
23. Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope. Richardson J; Moraillon A; Baud S; Cuisinier AM; Sonigo P; Pancino G J Virol; 1997 Dec; 71(12):9640-9. PubMed ID: 9371628 [TBL] [Abstract][Full Text] [Related]
24. Lack of protection against feline immunodeficiency virus infection among domestic cats in New Zealand vaccinated with the Fel-O-Vax® FIV vaccine. Stickney A; Ghosh S; Cave NJ; Dunowska M Vet Microbiol; 2020 Nov; 250():108865. PubMed ID: 33045631 [TBL] [Abstract][Full Text] [Related]
25. Vaccination against feline immunodeficiency virus using fixed infected cells. Verschoor EJ; van Vliet AL; Egberink HF; Hesselink W; van Alphen WE; Joosten I; Boog CJ; Horzinek MC; de Ronde A Vet Immunol Immunopathol; 1995 May; 46(1-2):139-49. PubMed ID: 7618254 [TBL] [Abstract][Full Text] [Related]
26. Vaccination with a feline immunodeficiency virus multiepitopic peptide induces cell-mediated and humoral immune responses in cats, but does not confer protection. Flynn JN; Cannon CA; Neil JC; Jarrett O J Virol; 1997 Oct; 71(10):7586-92. PubMed ID: 9311839 [TBL] [Abstract][Full Text] [Related]
27. Vaccination with an inactivated virulent feline immunodeficiency virus engineered to express high levels of Env. Hosie MJ; Klein D; Binley JM; Dunsford TH; Jarrett O; Neil JC; Knapp E; Giannecchini S; Matteucci D; Bendinelli M; Hoxie JA; Willett BJ J Virol; 2005 Feb; 79(3):1954-7. PubMed ID: 15650222 [TBL] [Abstract][Full Text] [Related]
28. Env-specific CTL predominate in cats protected from feline immunodeficiency virus infection by vaccination. Flynn JN; Keating P; Hosie MJ; Mackett M; Stephens EB; Beatty JA; Neil JC; Jarrett O J Immunol; 1996 Oct; 157(8):3658-65. PubMed ID: 8871667 [TBL] [Abstract][Full Text] [Related]
29. Feline immunodeficiency virus subunit vaccines that induce virus neutralising antibodies but no protection against challenge infection. Huisman W; Karlas JA; Siebelink KH; Huisman RC; de Ronde A; Francis MJ; Rimmelzwaan GF; Osterhaus AD Vaccine; 1998; 16(2-3):181-7. PubMed ID: 9607028 [TBL] [Abstract][Full Text] [Related]
30. Utilization of Feline ELISpot to Evaluate the Immunogenicity of a T Cell-Based FIV MAP Vaccine. Sahay B; Aranyos AM; McAvoy A; Yamamoto JK Methods Mol Biol; 2018; 1808():197-219. PubMed ID: 29956186 [TBL] [Abstract][Full Text] [Related]
31. Mutations in feline immunodeficiency (FIV) virus envelope gene V3-V5 regions in FIV-infected cats. Motokawa K; Hohdatsu T; Imori A; Arai S; Koyama H Vet Microbiol; 2005 Mar; 106(1-2):33-40. PubMed ID: 15737471 [TBL] [Abstract][Full Text] [Related]
32. A longitudinal study of feline immunodeficiency virus-specific cytotoxic T lymphocytes in experimentally infected cats, using antigen-specific induction. Beatty JA; Willett BJ; Gault EA; Jarrett O J Virol; 1996 Sep; 70(9):6199-206. PubMed ID: 8709246 [TBL] [Abstract][Full Text] [Related]
33. gag- and env-specific serum antibodies in cats after natural and experimental infection with feline immunodeficiency virus. Rimmelzwaan GF; Siebelink KH; Broos H; Drost GA; Weijer K; van Herwijnen R; Osterhaus AD Vet Microbiol; 1994 Mar; 39(1-2):153-65. PubMed ID: 8203121 [TBL] [Abstract][Full Text] [Related]
36. Targeted lymph node immunization can protect cats from a mucosal challenge with feline immunodeficiency virus. Finerty S; Stokes CR; Gruffydd-Jones TJ; Hillman TJ; Barr FJ; Harbour DA Vaccine; 2001 Oct; 20(1-2):49-58. PubMed ID: 11567745 [TBL] [Abstract][Full Text] [Related]
37. Neutralising antibody response in domestic cats immunised with a commercial feline immunodeficiency virus (FIV) vaccine. Bęczkowski PM; Harris M; Techakriengkrai N; Beatty JA; Willett BJ; Hosie MJ Vaccine; 2015 Feb; 33(8):977-84. PubMed ID: 25613718 [TBL] [Abstract][Full Text] [Related]
38. Differences in feline immunodeficiency virus host cell range correlate with envelope fusogenic properties. Pancino G; Castelot S; Sonigo P Virology; 1995 Feb; 206(2):796-806. PubMed ID: 7856093 [TBL] [Abstract][Full Text] [Related]
39. Molecular subtyping of feline immunodeficiency virus from cats in Melbourne. Iwata D; Holloway SA Aust Vet J; 2008 Oct; 86(10):385-9. PubMed ID: 18826508 [TBL] [Abstract][Full Text] [Related]
40. Passive antibody protection of cats against feline immunodeficiency virus infection. Hohdatsu T; Pu R; Torres BA; Trujillo S; Gardner MB; Yamamoto JK J Virol; 1993 Apr; 67(4):2344-8. PubMed ID: 8383246 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]